Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001373604-25-000063
Filing Date
2025-04-24
Accepted
2025-04-24 08:56:37
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 7510
2 BML LETTER TO BOARD bmlletter.htm EX-1 2481
  Complete submission text file 0001373604-25-000063.txt   11660
Mailing Address 65 E CEDAR - SUITE 2 ZIONSVILLE IN 46077
Business Address 65 E CEDAR - SUITE 2 ZIONSVILLE IN 46077 317-344-2447
BML Investment Partners, L.P. (Filed by) CIK: 0001373604 (see all company filings)

EIN.: 383708345 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D

Mailing Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5
Business Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5 (778) 331-0962
ESSA Pharma Inc. (Subject) CIK: 0001633932 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: SCHEDULE 13D | Act: 34 | File No.: 005-88939 | Film No.: 25863836
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)